X
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Xenon Pharmaceuticals Inc
NASDAQ:XENE
Price:
43.58 USD
-0.39%
Updated:
May 6, 2024
Xenon Pharmaceuticals Inc
Net Income (Common)
|
Xenon Pharmaceuticals Inc
Net Income (Common) Peer Comparison
Comparables:
ZYME
RPTX
FUSN
AUPH
EDT
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
X
|
Xenon Pharmaceuticals Inc
NASDAQ:XENE
|
Net Income (Common)
-$182.4m
|
CAGR 3-Years
-87%
|
CAGR 5-Years
-42%
|
CAGR 10-Years
N/A
|
|
|
Zymeworks Inc
NYSE:ZYME
|
Net Income (Common)
-$118.7m
|
CAGR 3-Years
13%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
Repare Therapeutics Inc
NASDAQ:RPTX
|
Net Income (Common)
-$93.8m
|
CAGR 3-Years
-21%
|
CAGR 5-Years
-46%
|
CAGR 10-Years
N/A
|
|
|
Fusion Pharmaceuticals Inc
NASDAQ:FUSN
|
Net Income (Common)
-$94.9m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-52%
|
CAGR 10-Years
N/A
|
|
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
Net Income (Common)
-$78m
|
CAGR 3-Years
9%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-40%
|
|
|
Spectral Medical Inc
TSX:EDT
|
Net Income (Common)
-CA$15.7m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-44%
|
CAGR 10-Years
-3%
|
See Also
What is Xenon Pharmaceuticals Inc's Net Income (Common)?
Net Income (Common)
-182.4m
USD
-182.4m
USD
Based on the financial report for Dec 31, 2023, Xenon Pharmaceuticals Inc's Net Income (Common) amounts to -182.4m USD.
What is Xenon Pharmaceuticals Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-42%
-42%
Over the last year, the Net Income (Common) growth was -46%. The average annual Net Income (Common) growth rates for Xenon Pharmaceuticals Inc have been -87% over the past three years , -42% over the past five years .
You don't have any saved screeners yet
